Opinion|Videos|September 30, 2024
Surgical and Radiotherapy Choices in Limited-Stage SCLC
Panelists discuss how the surgical approach to limited-stage small cell lung cancer varies, including the percentage of cases amenable to resection, the preference for lobectomy in stage I-IIA disease, and the role of mediastinal lymph node staging in shaping treatment strategies, alongside considerations for choosing between surgery and radiotherapy, the selection of systemic treatments, and the integration of prophylactic cranial irradiation in treatment plans.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your experience, what percentage of limited-stage disease is amenable to resection and does lobectomy remain the preferred procedure for stage I-IIA (T1-2, N0, M0) disease?
- How often does a surgeon operate on a small cell nodule, and what is the next step in treatment?
- To what degree does mediastinal lymph node staging influence your treatment path?
2. Under what circumstances would surgery vs radiotherapy (SABR ) be a preferred, definitive treatment choice for a patient with stage I-IIA small cell lung cancer (SCLC)?
- How do you approach frontline therapy?
- What factors inform your decision to select systemic treatment and concurrent radiotherapy vs sequential radiotherapy?
- How does prophylactic cranial irradiation factor into your treatment plan for patients with limited-stage SCLC?
Advertisement
Related to this article
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5